Crohn’s disease (CD) management increasingly recognizes dietary factors, especially ultra-processed foods containing emulsifiers—additives commonly used to improve texture and preservation. Our recent ADDapt clinical trial found that reducing dietary emulsifier intake significantly improves remission rates in CD patients. Yet, numerous patients benefited from emulsifier withdrawal, while some didn’t, further highlighting the urgent need for microbiome markers to predict dietary response. One of the approaches is to isolate and characterize the flagellated bacteria related to emulsifier-mediated chronic intestinal inflammation.
Related team publications: